Reuters: Regulatory News: FDA extends review of Novo Nordisk's Degludec by 3 mths

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

FDA extends review of Novo Nordisk's Degludec by 3 mths Jun 8th 2012, 05:56 COPENHAGEN, June 8 | Fri Jun 8, 2012 1:56am EDT COPENHAGEN, June 8 (Reuters) - Danish drugmaker Novo Nordisk , the world's biggest insulin maker, said on Friday that U.S. health regulators have extended their review of ultra-long-acting insulin products Degludec and DegludecPlus by three months to consider further data. A decision on the review of the drug candidates to treat type 1 and type 2 diabetes is now expected on Oct. 29. The U.S. Food and Drug Administration asked for further data clarification and analyses, and the company has submitted a substantial amount of additional data. "Due to the size and timing of these submissions the FDA considers them as major amendments to the (new drug applications)," the company said in a statement, adding that the agency had not requested additional clinical trials. Novo Nordisk has also filed for approval of the two products with the European Medicines Agency and regulators in Japan, Canada, Switzerland and some other countries, it said. It first filed for approval with the FDA in Sept. 2011.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions